Mirum Pharmaceuticals, Inc. (MIRM): Shareholders' Equity
$314.69M
As of 2025-12-31
-$10.42M
As of 2026-06-30
+30.4%
3-year compound annual growth
+12.8%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $314.69M | +39.5% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $225.64M | -9.3% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $248.67M | +75.1% | 2026-02-25, Balance as of period end |
| 2022-12-31 | $142.04M | +18.2% | 2025-02-26, Balance as of period end |
| 2021-12-31 | $120.21M | -30.1% | 2024-03-15, Balance as of period end |
| 2020-12-31 | $172.09M | +32.0% | 2022-03-09, Balance as of period end |
| 2019-12-31 | $130.35M | n/m | 2021-03-09, Balance as of period end |
| 2018-12-31 | -$17.31M | n/a | 2020-03-12, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $314.69M | +39.5% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | -$2.09B | n/m |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $1.25B | +62.1% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $114.83M | +94.4% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $300.13M | +14.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $161.55M | +0.3% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $715.50M | -14.9% |
| Insmed Inc (INSM) | 2025-12-31 | $738.98M | +158.9% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $1.27B | -7.1% |
Compare MIRM, BBIO, HCM, TVTX side by side · Screen every company in Pharmaceutical Preparations ↗